Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Isavuconazole’s (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h resp...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2023-10, Vol.67 (10), p.e0061323-e0061323
Main Authors: Caballero-Bermejo, Antonio F., Darnaude-Ximénez, Ignacio, Aguilar-Pérez, Myriam, Gomez-Lopez, Alicia, Sancho-López, Aránzazu, López García-Gallo, Cristina, Díaz Nuevo, Gema, Diago-Sempere, Elena, Ruiz-Antorán, Belén, Avendaño-Solá, Cristina, Ussetti-Gil, Piedad
Format: Article
Language:English
Subjects:
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Isavuconazole’s (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.00613-23